David M. O’Malley

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute — United States

Medicine · Health Sciences

87h-index30.9kcitations879works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(459), Endometrial and Cervical Cancer Treatments(196), PARP inhibition in cancer therapy(186), Intraperitoneal and Appendiceal Malignancies(69), Cancer Genomics and Diagnostics(59)

Publications874 total

HO-3867 reprograms the tumor microenvironment through extracellular vesicle regulation in ovarian cancer
Academia oncology.·2026Open Access
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
Journal for ImmunoTherapy of Cancer·2026Open Access
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201
Future Oncology·2025· 1 citedOpen Access
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Journal of Clinical Oncology·2025· 2 cited
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma
Clinical Cancer Research·2025Open Access
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
2025Open Access
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
2025Open Access
546 Sarilumab as a potential mitigator of ubamatamab (MUC16×CD3)-induced cytokine release syndrome (CRS) in patients with advanced ovarian cancer (OC) or endometrial cancer (EC)
Regular and Young Investigator Award Abstracts·2025Open Access
A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL TO COMPARE RINATABART SESUTECAN VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER: RAINFOL™-02 (ENGOT-OV86/GOG-3107)
International Journal of Gynecological Cancer·2025
S63 Metabolic profiling of peripheral blood and tissue specific immune alterations in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)
2025
FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)
International Journal of Gynecological Cancer·2025
Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
Journal of Clinical Oncology·2025
Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
Molecular Cancer Therapeutics·2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study
Annals of Oncology·2025Open Access
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Journal of Clinical Oncology·2025
Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
Obstetrical & Gynecological Survey·2025
Assessment of probiotic and prebiotic use in gynecologic cancer patients: a systematic review
American Journal of Obstetrics and Gynecology·2025
Abstract B020: Unveiling the tumor-associated microbiome in ovarian cancer: Correlations with clinical features, outcomes, and treatment strategies
Cancer Research·2025
Carboplatin and mirvetuximab soravtansine in first-line treatment of patients receiving neoadjuvant chemotherapy for folate receptor alpha positive advanced-stage ovarian, fallopian tube or primary peritoneal cancer: A single-arm phase II study
Gynecologic Oncology·2025
Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok
Gynecologic Oncology·2025
page 1 of 44Next →

Frequent Co-authors

Amit M. Oza(12), Richard T. Penson(11), Robert L. Coleman(11), Deborah K. Armstrong(9), Isabelle Ray‐Coquard(8), Susana Banerjee(8), Clare L. Scott(8), Ana Oaknin(8), Iain A. McNeish(8), Sandro Pignata(7), Anne Floquet(7), Ursula A. Matulonis(7), Ronald R. Sederoff(7), Kathleen N. Moore(7), Michael Friedländer(6), Nicoletta Colombo(6), Diane Provencher(6), Elizabeth M. Swisher(6), Gottfried E. Konecny(6), Lara Maloney(6)